NASDAQ:URGN - Urogen Pharma Stock Price, Price Target & More

$57.19 -0.69 (-1.19 %)
(As of 04/20/2018 04:24 AM ET)
Previous Close$57.88
Today's Range$55.81 - $58.98
52-Week Range$13.01 - $66.38
Volume334,900 shs
Average Volume140,073 shs
Market Capitalization$832.78 million
P/E Ratio-26.72
Dividend YieldN/A
BetaN/A

About Urogen Pharma (NASDAQ:URGN)

Urogen Pharma logoUrogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC). Its other clinical-stage drug candidates include Vesimune and BotuGel. Vesimune is a formulation of the toll-like receptor7 (TLR7) agonist Imiquimod for local intravesical delivery for the treatment of Carcinoma In-Situ. BotuGel is an intravesical sustained release formulation of botulinum toxin for Overactive Bladder (OAB) and Interstitial Cystitis (IC). Its platform technologies include: RTGel and Immunotherapy.

Receive URGN News and Ratings via Email

Sign-up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:URGN
CUSIPN/A
Phone972-9770-7601

Debt

Debt-to-Equity RatioN/A
Current Ratio10.59%
Quick Ratio10.55%

Price-To-Earnings

Trailing P/E Ratio-26.72
Forward P/E Ratio-17.82
P/E GrowthN/A

Sales & Book Value

Annual Sales$8.16 million
Price / Sales96.37
Cash FlowN/A
Price / CashN/A
Book Value$4.98 per share
Price / Book11.48

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees33
Outstanding Shares13,750,000

How to Become a New Pot Stock Millionaire

Urogen Pharma (NASDAQ:URGN) Frequently Asked Questions

What is Urogen Pharma's stock symbol?

Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."

How were Urogen Pharma's earnings last quarter?

Urogen Pharma Ltd (NASDAQ:URGN) announced its quarterly earnings results on Thursday, March, 15th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.65) by $0.09. The business earned $0.33 million during the quarter. View Urogen Pharma's Earnings History.

When is Urogen Pharma's next earnings date?

Urogen Pharma is scheduled to release their next quarterly earnings announcement on Thursday, June, 21st 2018. View Earnings Estimates for Urogen Pharma.

What price target have analysts set for URGN?

7 analysts have issued 12 month price targets for Urogen Pharma's stock. Their predictions range from $25.00 to $75.00. On average, they anticipate Urogen Pharma's share price to reach $50.60 in the next twelve months. View Analyst Ratings for Urogen Pharma.

What are Wall Street analysts saying about Urogen Pharma stock?

Here are some recent quotes from research analysts about Urogen Pharma stock:
  • 1. Cowen Inc analysts commented, "URGN presented updates for MitoGel’s Phase 3 OLYMPUS trial (topline data in 2Q18)." (11/15/2017)
  • 2. According to Zacks Investment Research, "UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel. " (10/18/2017)

Who are some of Urogen Pharma's key competitors?

Who are Urogen Pharma's key executives?

Urogen Pharma's management team includes the folowing people:
  • Arie S. Belldegrun, Chairman of the Board (Age 67)
  • Ron Bentsur, Chief Executive Officer, Director (Age 51)
  • Gary S. Titus, Chief Financial Officer (Age 57)
  • Gil Hakim, President - Israeli Operation (Age 47)
  • Chaim Hurvitz, Director (Age 56)
  • Ran Nussbaum, Director (Age 44)
  • Kathryn E. Falberg, Independent Director (Age 56)
  • Stuart Holden M.D., Independent Director (Age 74)
  • Pini Orbach Ph.D., Independent Director (Age 52)

When did Urogen Pharma IPO?

(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

Has Urogen Pharma been receiving favorable news coverage?

Media coverage about URGN stock has been trending somewhat positive recently, Accern reports. The research group rates the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Urogen Pharma earned a daily sentiment score of 0.17 on Accern's scale. They also assigned media coverage about the company an impact score of 45.71 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Urogen Pharma?

Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Urogen Pharma's stock price today?

One share of URGN stock can currently be purchased for approximately $57.19.

How big of a company is Urogen Pharma?

Urogen Pharma has a market capitalization of $832.78 million and generates $8.16 million in revenue each year. The company earns $-20,000,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis. Urogen Pharma employs 33 workers across the globe.

How can I contact Urogen Pharma?

Urogen Pharma's mailing address is 9 HaTaasiya St, Raanana L3, 4365007. The company can be reached via phone at 972-9770-7601 or via email at [email protected]


MarketBeat Community Rating for Urogen Pharma (URGN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  94 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  191
MarketBeat's community ratings are surveys of what our community members think about Urogen Pharma and other stocks. Vote "Outperform" if you believe URGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe URGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Urogen Pharma (NASDAQ:URGN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Urogen Pharma in the last 12 months. Their average twelve-month price target is $50.60, suggesting that the stock has a possible downside of 11.52%. The high price target for URGN is $75.00 and the low price target for URGN is $25.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.712.713.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $50.60$48.00$42.80$31.3333
Price Target Upside: 11.52% downside9.69% downside15.02% upside6.72% upside

Urogen Pharma (NASDAQ:URGN) Consensus Price Target History

Price Target History for Urogen Pharma (NASDAQ:URGN)

Urogen Pharma (NASDAQ:URGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2018UBSUpgradeMarket Perform -> OutperformHighView Rating Details
4/4/2018Raymond JamesUpgradeMarket Perform -> OutperformHighView Rating Details
4/3/2018OppenheimerReiterated RatingBuy$62.00 -> $75.00HighView Rating Details
3/19/2018Jefferies GroupReiterated RatingBuyLowView Rating Details
3/16/2018Ladenburg ThalmannReiterated RatingBuy -> Buy$65.00HighView Rating Details
11/15/2017CowenReiterated RatingBuyN/AView Rating Details
11/15/2017CIBCReiterated RatingOutperform -> Outperform$32.00 -> $51.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Urogen Pharma (NASDAQ:URGN) Earnings History and Estimates Chart

Earnings by Quarter for Urogen Pharma (NASDAQ:URGN)

Urogen Pharma (NASDAQ:URGN) Earnings Estimates

Current Year EPS Consensus Estimate: $-3.21 EPS
Next Year EPS Consensus Estimate: $-2.74 EPS

Urogen Pharma (NASDAQ URGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
6/21/2018        
3/15/2018n/a($0.65)($0.74)$0.33 millionViewListenView Earnings Details
11/14/2017Q3 2017$0.08($0.02)$7.67 million$7.81 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.46)($0.70)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Urogen Pharma (NASDAQ:URGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Urogen Pharma (NASDAQ URGN) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 50.49%
Insider Trading History for Urogen Pharma (NASDAQ:URGN)
Institutional Ownership by Quarter for Urogen Pharma (NASDAQ:URGN)

Urogen Pharma (NASDAQ URGN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/28/2017Proquest Investments Iv, L.P.Major ShareholderSell209,298$40.60$8,497,498.80View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Urogen Pharma (NASDAQ URGN) News Headlines

Source:
DateHeadline
-$0.73 Earnings Per Share Expected for Urogen Pharma Ltd (URGN) This Quarter-$0.73 Earnings Per Share Expected for Urogen Pharma Ltd (URGN) This Quarter
www.americanbankingnews.com - April 15 at 11:15 AM
Zacks Investment Research Upgrades Urogen Pharma (URGN) to BuyZacks Investment Research Upgrades Urogen Pharma (URGN) to Buy
www.americanbankingnews.com - April 14 at 10:05 AM
Urogen Pharma Ltd (URGN) Given Consensus Recommendation of "Buy" by BrokeragesUrogen Pharma Ltd (URGN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 14 at 3:30 AM
Analyzing Urogen Pharma (URGN) and Its CompetitorsAnalyzing Urogen Pharma (URGN) and Its Competitors
www.americanbankingnews.com - April 13 at 5:21 PM
Urogen Pharma (URGN) Upgraded at Zacks Investment ResearchUrogen Pharma (URGN) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 6 at 1:55 PM
UroGen Pharma (URGN) Presents Data From Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 for Non-Surgical Treatment of UTUCUroGen Pharma (URGN) Presents Data From Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 for Non-Surgical Treatment of UTUC
www.streetinsider.com - April 4 at 5:06 PM
Today’s Research Reports on Stocks to Watch: UroGen Pharma and NovartisToday’s Research Reports on Stocks to Watch: UroGen Pharma and Novartis
finance.yahoo.com - April 4 at 5:06 PM
Urogen Pharma (URGN) Upgraded at UBSUrogen Pharma (URGN) Upgraded at UBS
www.americanbankingnews.com - April 4 at 12:49 PM
Urogen Pharma (URGN) Lifted to "Buy" at Raymond James FinancialUrogen Pharma (URGN) Lifted to "Buy" at Raymond James Financial
www.americanbankingnews.com - April 4 at 8:04 AM
Urogen Pharmas (URGN) Buy Rating Reiterated at OppenheimerUrogen Pharma's (URGN) Buy Rating Reiterated at Oppenheimer
www.americanbankingnews.com - April 3 at 10:40 AM
UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel™) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)
finance.yahoo.com - April 3 at 9:49 AM
Urogen Pharma (URGN) & Its Rivals Critical AnalysisUrogen Pharma (URGN) & Its Rivals Critical Analysis
www.americanbankingnews.com - April 2 at 1:30 AM
-$0.75 EPS Expected for Urogen Pharma Ltd (URGN) This Quarter-$0.75 EPS Expected for Urogen Pharma Ltd (URGN) This Quarter
www.americanbankingnews.com - March 29 at 1:16 PM
Urogen Pharmas (URGN) "Buy" Rating Reaffirmed at OppenheimerUrogen Pharma's (URGN) "Buy" Rating Reaffirmed at Oppenheimer
www.americanbankingnews.com - March 22 at 4:05 PM
Urogen Pharma Ltd (URGN) Receives Consensus Rating of "Buy" from AnalystsUrogen Pharma Ltd (URGN) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 20 at 3:34 AM
Urogen Pharma (URGN) Given Buy Rating at Jefferies GroupUrogen Pharma (URGN) Given Buy Rating at Jefferies Group
www.americanbankingnews.com - March 19 at 5:02 PM
Ladenburg Thalmann Financial Services Analysts Give Urogen Pharma (URGN) a $65.00 Price TargetLadenburg Thalmann Financial Services Analysts Give Urogen Pharma (URGN) a $65.00 Price Target
www.americanbankingnews.com - March 16 at 8:20 PM
Oppenheimer Reiterates "$62.00" Price Target for Urogen Pharma (URGN)Oppenheimer Reiterates "$62.00" Price Target for Urogen Pharma (URGN)
www.americanbankingnews.com - March 15 at 7:06 PM
UroGen Reports Fourth Quarter and Full Year 2017 Financial ResultsUroGen Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 15 at 4:54 PM
Urogen Pharma (URGN) Releases Quarterly  Earnings Results, Misses Expectations By $0.09 EPSUrogen Pharma (URGN) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS
www.americanbankingnews.com - March 15 at 2:24 PM
Urogen Pharma (URGN) Set to Announce Earnings on ThursdayUrogen Pharma (URGN) Set to Announce Earnings on Thursday
www.americanbankingnews.com - March 9 at 11:48 PM
UroGen to Present at March 2018 Investor ConferencesUroGen to Present at March 2018 Investor Conferences
finance.yahoo.com - March 7 at 9:38 AM
Spark Investment Management LLC Grows Position in Urogen Pharma Ltd (URGN)Spark Investment Management LLC Grows Position in Urogen Pharma Ltd (URGN)
www.americanbankingnews.com - March 1 at 6:50 PM
Zacks: Brokerages Anticipate Urogen Pharma Ltd (URGN) to Announce -$0.66 Earnings Per ShareZacks: Brokerages Anticipate Urogen Pharma Ltd (URGN) to Announce -$0.66 Earnings Per Share
www.americanbankingnews.com - February 23 at 2:20 PM
Research Analysts Set Expectations for Urogen Pharma Ltds Q4 2017 Earnings (URGN)Research Analysts Set Expectations for Urogen Pharma Ltd's Q4 2017 Earnings (URGN)
www.americanbankingnews.com - February 15 at 8:02 AM
Urogen Pharma (URGN) and Tyme Technologies (TYME) Head to Head ReviewUrogen Pharma (URGN) and Tyme Technologies (TYME) Head to Head Review
www.americanbankingnews.com - February 14 at 9:08 PM
Research Analysts Issue Forecasts for Urogen Pharma Ltds FY2022 Earnings (URGN)Research Analysts Issue Forecasts for Urogen Pharma Ltd's FY2022 Earnings (URGN)
www.americanbankingnews.com - February 14 at 4:12 PM
UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating OfficerUroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Officer
finance.yahoo.com - February 14 at 9:08 AM
Zacks: Brokerages Anticipate Urogen Pharma Ltd (URGN) to Announce -$0.68 Earnings Per ShareZacks: Brokerages Anticipate Urogen Pharma Ltd (URGN) to Announce -$0.68 Earnings Per Share
www.americanbankingnews.com - February 6 at 12:36 PM
Urogen Pharma Ltd (URGN) Given Average Recommendation of "Buy" by AnalystsUrogen Pharma Ltd (URGN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 29 at 3:30 AM
UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters OptionUroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option
finance.yahoo.com - January 23 at 4:06 PM
UroGen Pharma Announces Pricing of Public Offering of Ordinary SharesUroGen Pharma Announces Pricing of Public Offering of Ordinary Shares
finance.yahoo.com - January 19 at 9:58 AM
UroGen Pharma Announces Proposed Public Offering of Ordinary SharesUroGen Pharma Announces Proposed Public Offering of Ordinary Shares
finance.yahoo.com - January 16 at 5:42 PM
UroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs OfficerUroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer
finance.yahoo.com - January 8 at 10:49 AM
Urogen Pharma Ltd (URGN) Receives Average Rating of "Buy" from BrokeragesUrogen Pharma Ltd (URGN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - January 4 at 4:02 AM
Urogen Pharma (URGN) Research Coverage Started at Ladenburg Thalmann Financial ServicesUrogen Pharma (URGN) Research Coverage Started at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - January 2 at 11:04 AM
UroGen Pharma to Present at the 36th Annual J.P. Morgan Healthcare ConferenceUroGen Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 9:01 AM
UroGen Pharma Ltd. breached its 50 day moving average in a Bearish Manner : URGN-US : January 1, 2018UroGen Pharma Ltd. breached its 50 day moving average in a Bearish Manner : URGN-US : January 1, 2018
finance.yahoo.com - January 1 at 9:01 AM
Urogen Pharma Ltd (URGN) Expected to Announce Earnings of -$0.68 Per ShareUrogen Pharma Ltd (URGN) Expected to Announce Earnings of -$0.68 Per Share
www.americanbankingnews.com - December 18 at 3:26 AM
UroGen Pharma Expands Clinical Development Leadership TeamUroGen Pharma Expands Clinical Development Leadership Team
finance.yahoo.com - December 12 at 9:27 AM
-$0.68 Earnings Per Share Expected for Urogen Pharma Ltd (URGN) This Quarter-$0.68 Earnings Per Share Expected for Urogen Pharma Ltd (URGN) This Quarter
www.americanbankingnews.com - November 30 at 1:26 AM
Proquest Investments Iv, L.P. Sells 209,298 Shares of Urogen Pharma Ltd (URGN) StockProquest Investments Iv, L.P. Sells 209,298 Shares of Urogen Pharma Ltd (URGN) Stock
www.americanbankingnews.com - November 29 at 7:24 PM
UroGen Pharma Announces Oral Presentation at Society of Urologic Oncology (SUO) Annual MeetingUroGen Pharma Announces Oral Presentation at Society of Urologic Oncology (SUO) Annual Meeting
finance.yahoo.com - November 27 at 3:46 PM
Wired News - Portola Pharmaceuticals Provides Update On Commercial Launch of Bevyxxa(R)Wired News - Portola Pharmaceuticals Provides Update On Commercial Launch of Bevyxxa(R)
finance.yahoo.com - November 27 at 8:30 AM
UROGEN PHARMA (URGN) Given a $51.00 Price Target by Oppenheimer Holdings, Inc. AnalystsUROGEN PHARMA (URGN) Given a $51.00 Price Target by Oppenheimer Holdings, Inc. Analysts
www.americanbankingnews.com - November 19 at 10:20 PM
UROGEN PHARMA (URGN) Downgraded to "Market Perform" at UBS AGUROGEN PHARMA (URGN) Downgraded to "Market Perform" at UBS AG
www.americanbankingnews.com - November 19 at 6:56 PM
Q4 2017 Earnings Estimate for Urogen Pharma (URGN) Issued By Jefferies GroupQ4 2017 Earnings Estimate for Urogen Pharma (URGN) Issued By Jefferies Group
www.americanbankingnews.com - November 17 at 10:12 PM
FY2017 EPS Estimates for Urogen Pharma Decreased by Oppenheimer Holdings (URGN)FY2017 EPS Estimates for Urogen Pharma Decreased by Oppenheimer Holdings (URGN)
www.americanbankingnews.com - November 17 at 7:12 PM
Raymond James Downgrades UroGen Pharma (URGN) to Market PerformRaymond James Downgrades UroGen Pharma (URGN) to Market Perform
www.streetinsider.com - November 16 at 9:40 AM
Urogen Pharmas (URGN) "Buy" Rating Reiterated at Cowen and CompanyUrogen Pharma's (URGN) "Buy" Rating Reiterated at Cowen and Company
www.americanbankingnews.com - November 15 at 11:36 PM

SEC Filings

Urogen Pharma (NASDAQ:URGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Urogen Pharma (NASDAQ:URGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Urogen Pharma (NASDAQ URGN) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.